Hepatology
103.Gupta AK, et al., Shear NH, Hepatitis associated with terbinafine therapy: three case reports and a review of the literature, Clin Exp Dermatol, 1998;23:64–7.
104.Bonnet F, et al., A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997–1999, Clin Infect Dis, 2002;35:1231–7.
105.Nunez M, Hepatotoxicity of antiretrovirals: incidence, mechanisms and management, J Hepatol, 2006;44:S132–9.
106.Servin-Abad L, et al., Liver enzymes elevation after HAART in HIV-HCV co-infection, J Viral Hepat, 2005;12:429–34.
107.Lai AR, et al., Antiretroviral medication considerations for individuals coinfected with HIV and hepatitis C virus, AIDS Patient Care STDS, 2006;20:678–92.
108.den Brinker M, et al., Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection, AIDS, 2000;14:2895–902.
109.Sulkowski MS, Viral hepatitis and HIV coinfection, J Hepatol, 2008;48:353–67.
110.Labarga P, et al., Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients, J Infect Dis, 2007;196:670–6.
111.Shah T, et al., Resolution of hepatitis C virus-induced steatosis improves tolerability of antiretroviral drugs associated with hepatotoxicity in an HIV-infected individual, J Infect Dis, 2008;197:932–3.
112.Martinez E, et al., Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy, AIDS, 2001;15:1261–8.
113.Martin AM, et al., Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts, AIDS, 2005;19:97–9.
114.Dieterich DT, et al., Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors, Clin Infect Dis, 2004;38(Suppl 2):S80–9.
115.Sanne I, et al., Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects, J Infect Dis, 2005;191:825–9.
116.Torti C, et al., Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients, Drug Saf, 2007;30:1161–9.
117.De Lazzari E, et al., Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts, HIV Med, 2008;9:221–6.
118.Knobel H, et al., Risk of side effects associated with the use of nevirapine in treatment-naive patients, with respect to gender and CD4 cell count, HIV Med, 2008;9:14–8.
119.Medrano J, et al., Risk for immune-mediated liver reactions by nevirapine revisited, AIDS Rev, 2008;10:110–5.
120.de Maat MM, et al., Case series of acute hepatitis in a non- selected group of HIV-infected patients on nevirapine- containing antiretroviral treatment, AIDS, 2003;17:2209–14.
121.Mallal S, et al., Association between presence of HLA- B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV- 1 reverse-transcriptase inhibitor abacavir, Lancet, 2002;359:727–32.
122.Phillips EJ, et al., HLA and drug-induced toxicity, Curr Opin Mol Ther, 2009;11:231–42.
123.Johnson AA, et al., Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase, J Biol Chem, 2001;276:40847–57.
124.Sulkowski MS, et al., Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus, AIDS, 2005;19:585–92.
125.Miller KD, et al., Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases, Ann Intern Med, 2000;133:192–6.
126.Sulkowski MS, et al., Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection, JAMA, 2000;283:74–80.
127.Aceti A, et al., Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus
infection, J Acquir Immune Defic Syndr, 2002;29:41–8.
128.Sulkowski MS, et al., Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir, AIDS, 2004;18:2277–84.
129.Cooper CL, et al., Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus, Clin Infect Dis, 2002;34:1259–63.
130.Zucker SD, et al., Mechanism of indinavir-induced hyperbilirubinemia, Proc Natl Acad Sci U S A, 2001;98:12671–6.
131.Graham DJ, Green L, Senior JR, Nourjah P, Troglitazone- induced liver failure: a case study, Am J Med, 2003;114:299–306.
132.Chan KA, et al., A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents, Arch Intern Med, 2003;163:728–34.
133.Marcy TR, et al., Second-generation thiazolidinediones and hepatotoxicity, Ann Pharmacother, 2004;38:1419–23.
134.Al-Salman J, et al., Hepatocellular injury in a patient receiving rosiglitazone. A case report, Ann Intern Med, 2000;132:121–4.
135.Forman LM, et al., Hepatic failure in a patient taking rosiglitazone, Ann Intern Med, 2000;132:118–21.
136.Farley-Hills E, et al., Fatal liver failure associated with pioglitazone, BMJ, 2004;329:429.
137.Chase MP, et al., Pioglitazone-associated fulminant hepatic failure, Am J Gastroenterol, 2002;97:502–3.
138.Sitruk V, et al., [Acute cholestatic hepatitis induced by glimepiride], Gastroenterol Clin Biol, 2000;24:1233–4.
139.Heurgue A, et al., [Glimepiride-induced cute cholestatic hepatitis], Ann Endocrinol (Paris), 2004;65:174–5.
140.Chounta A, et al., Cholestatic liver injury after glimepiride therapy, J Hepatol, 2005;42:944–6.
141.Tolman KG, The liver and lovastatin, Am J Cardiol, 2002;89:1374–80.
142.Law M, et al., Statin safety: a systematic review, Am J Cardiol, 2006;97:52C–60C.
143.Talbert RL, Safety issues with statin therapy, J Am Pharm Assoc, 2006;46:479–88; quiz 488–90.
144.Cohen DE, et al., An assessment of statin safety by hepatologists, Am J Cardiol, 2006;97:77C–81C.
145.Alla V, et al., Autoimmune hepatitis triggered by statins, J Clin Gastroenterol, 2006;40:757–61.
146.Pelli N, et al., Autoimmune hepatitis revealed by atorvastatin, Eur J Gastroenterol Hepatol, 2003;15:921–4.
147.Wolters LM, et al., Rosuvastatin-associated hepatitis with autoimmune features, Eur J Gastroenterol Hepatol, 2005;17:589–90.
148.Graziadei IW, et al., Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis, Lupus, 2003;12:409–12.
149.Khorashadi S, et al., Incidence of statin hepatotoxicity in patients with hepatitis C, Clin Gastroenterol Hepatol, 2006;4:902– 7; quiz 806.
150.Segarra-Newnham M, et al., Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus, Pharmacotherapy, 2007;27:845–51.
151.Dujovne CA, Ettinger MP, McNeer JF, et al., Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia, Am J Cardiol, 2002;90:1092–7.
152.Gagne C, et al., Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia, Am J Cardiol, 2002;90:1084–91.
153.Pandor A, et al., Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta- analysis of randomized controlled trials, J Intern Med, 2009;265:568–80.
154.Stolk MF, et al., Severe hepatic side effects of ezetimibe, Clin Gastroenterol Hepatol, 2006;4:908–11.
155.Seeff LB, Herbal hepatotoxicity, Clin Liver Dis, 2007;11:577–96, vii.
156.Kessler RC, et al., Short screening scales to monitor population prevalences and trends in non-specific
psychological distress, Psychol Med, 2002;32:959–76.
157.Stickel F, et al., Herbal hepatotoxicity, J Hepatol, 2005;43:901–10.
158.Schoepfer AM, et al., Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products, J Hepatol, 2007;47:521–6.
159.Stickel F, et al., Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis, J Hepatol, 2009;50:111–7.
160.Iwasa M, et al., pirulina-associated hepatotoxicity, Am J Gastroenterol, 2002;97:3212–3.
161.Favreau JT, et al., Severe hepatotoxicity associated with the dietary supplement LipoKinetix, Ann Intern Med, 2002;136:590–5.
162.Estes JD, et al., High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure, Arch Surg, 2003;138:852–8.
163.Itoh S, et al., Liver injuries induced by herbal medicine, syo- saiko-to (xiao-chai-hu-tang), Dig Dis Sci, 1995;40:1845–8.
164.Hsu LM, et al., Acute hepatitis induced by Chinese hepatoprotective herb, xiao-chai-hu-tang, J Chin Med Assoc, 2006;69:86–8.
165.Kamiyama T, et al., Autoimmune hepatitis triggered by administration of an herbal medicine, Am J Gastroenterol, 1997;92:703–4.
166.Gordon DW, et al., Chaparral ingestion. The broadening spectrum of liver injury caused by herbal medications, JAMA, 1995;273:489–90.
167.Levy C, et al., Drug-induced cholestasis, Clin Liver Dis, 2003;7:311–30.
168.Stickel F, et al., The efficacy and safety of comfrey, Public Health Nutr, 2000;3:501–8.
169.Benninger J, et al., Acute hepatitis induced by greater celandine (Chelidonium majus), Gastroenterology, 1999;117:1234–7.
170.Stickel F, et al., Acute hepatitis induced by Greater Celandine (Chelidonium majus), Scand J Gastroenterol, 2003;38:565–8.
171.Stickel F, et al., Hepatitis induced by Kava (Piper methysticum rhizoma), J Hepatol, 2003;39:62–7.
172.Nadir A, et al., Cascara sagrada-induced intrahepatic cholestasis causing portal hypertension: case report and review of herbal hepatotoxicity, Am J Gastroenterol, 2000;95:3634–7.
173.Castot A, et al., [Hepatitis observed during a treatment with a drug or tea containing Wild Germander. Evaluation of 26 cases reported to the Regional Centers of Pharmacovigilance], Gastroenterol Clin Biol, 1992;16:916–22.
174.Larrey D, et al., Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity, Ann Intern Med, 1992;117:129–32.
175.Pauwels A, Thierman-Duffaud D, Azanowsky JM, et al., [Acute hepatitis caused by wild germander. Hepatotoxicity of herbal remedies. Two cases], Gastroenterol Clin Biol, 1992;16:92–5.
176.Sundaresan PR, et al., Isolation and characterisation of selected germander diterpenoids from authenticated Teucrium chamaedrys and T. canadense by HPLC, HPLC-mS and NMR, Phytochem Anal, 2006;17:243–50.
177.Woolf GM, et al., Acute hepatitis associated with the Chinese herbal product jin bu huan, Ann Intern Med, 1994;121:729–35.
178.Horowitz RS, et al., The clinical spectrum of Jin Bu Huan toxicity, Arch Intern Med, 1996;156:899–903.
179.Picciotto A, et al., Chronic hepatitis induced by Jin Bu Huan, J Hepatol, 1998;28:165–7.
180.Nadir A, et al., Acute hepatitis associated with the use of a Chinese herbal product, ma-huang, Am J Gastroenterol, 1996;91:1436–8.
181.Borum ML, Fulminant exacerbation of autoimmune hepatitis after the use of ma huang, Am J Gastroenterol, 2001;96:1654–5.
182.Neff GW, et al., Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid, J Hepatol, 2004;41:1062–4.
80
US GASTROENTEROLOGY & HEPATOLOGY REVIEW
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100